A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

NCT07229638 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: SHR-9839(sc) For Injection

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.